FDA Accepts sBLA of Dostarlimab/Chemo to Include All Advanced Endometrial Cancer
The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.